Print this page
-
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations.
Protocol: 112008Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Leukemia, not otherwise specified -
Pediatric Acute Leukemia (PedAL) Screening Trial: Developing New Therapies for Relapsed Leukemias.
Protocol: 112204Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Leukemia, not otherwise specified -
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma.
Protocol: 112305Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Hodgkin's Lymphoma -
A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy.
Protocol: 112308Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Leukemia, other -
A Phase 2 Study of Blinatumomab in Combination with Chemotherapy for Infants with Newly Diagnosed Acute Lymphoblastic Leukemia with Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax.
Protocol: 112507Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Lymphoid Leukemia -
An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors with Blinatumomab in Patients with Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia.
Protocol: 112510Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Leukemia, other -
A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL).
Protocol: 112512Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Lymphoid Leukemia -
Characterizing Lymphoma Survivors Experiences, Needs, and Preferences During the Transition to Cancer Survivorship: The Survivor Health Check Program Development Trial.
Protocol: 132203Principal Investigator:
- Sharon Manne
Applicable Disease Sites: Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma